Search results
Pacira (PCRX) Loses -17.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks via Yahoo Finance· 1 year agoPacira (PCRX) has become technically an oversold stock now, which implies exhaustion of the heavy...
Pacira BioSciences (NASDAQ:PCRX) stock falls 4.1% in past week as three-year earnings and...
Simply Wall St. via Yahoo Finance· 3 weeks agoThe truth is that if you invest for long enough, you're going to end up with some losing stocks. But...
Unveiling Pacira BioSciences (PCRX)'s Value: Is It Really Priced Right? A Comprehensive Guide
GuruFocus.com via Yahoo Finance· 7 months agoWith a day's loss of -2.26%, a 3-month loss of -17.45%, and a Loss Per Share of 0.16, Pacira...
Here's Why Pacira (PCRX) is a Strong Growth Stock
Zacks via Yahoo Finance· 2 years agoTaking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Achieving those goals is made...
Here's Why You Should Add Pacira (PCRX) Stock to Your Portfolio
Zacks via Yahoo Finance· 12 months agoPacira (PCRX) is witnessing strong growth on the back of its lead product, Exparel. Potential label...
Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock's Been Sliding But Fundamentals Look Decent: Will The...
Simply Wall St. via Yahoo Finance· 1 year agoIt is hard to get excited after looking at Pacira BioSciences' (NASDAQ:PCRX) recent performance,...
Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
Zacks via Yahoo Finance· 2 months agoPacira (PCRX) receives the FDA's RMAT designation for its gene-therapy product candidate, PCRX-201,...
Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues
Zacks via Yahoo Finance· 2 months agoPacira BioSciences, Inc. PCRX reported fourth-quarter 2023 adjusted earnings of 89 cents per share,...
Pacira (PCRX) Lags Q3 Earnings Estimates
Zacks via Yahoo Finance· 1 year agoPacira (PCRX) delivered earnings and revenue surprises of -12.33% and 0.10%, respectively, for the quarter ended September 2022. Do the numbers hold...
Are Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Fundamentals Good Enough to Warrant Buying Given The...
Simply Wall St. via Yahoo Finance· 6 months agoIt is hard to get excited after looking at Pacira BioSciences' (NASDAQ:PCRX) recent performance,...